Merck KGaA: A Diversified Science Platform in Transition

The most important judgment is this: the 2026 weakness is real, but it is not the whole story. The 2025-26 selloff was directionally understandable, yet the market has also shown that it will pay up again when Life Science and Electronics visibly outrun the Mavenclad damage. The current share price is best understood as a fair, somewhat awkward middle ground that assumes Merck is neither broken nor fully rerated. For existing holders, that supports patience; for new capital, it argues for more discipline.

Company vertical history, business model, and financial profile

Merck’s origins matter because they explain both its longevity and its governance. The group traces its roots to 1668, when Friedrich Jacob Merck acquired the Engel-Apotheke in Darmstadt. Merck’s own historical materials describe that pharmacy as the historic core of what became the world’s oldest pharmaceutical and chemical company, and the 2023 prospectus still notes that the pharmacy remains family property. The company stayed privately held for centuries before its modern capital-markets form arrived much later.

The modern listed company dates from 1995. Merck’s investor page states that the first listing was on October 20, 1995, with 39,999,999 shares issued at DM 54.00, or €27.61, and that the stock is listed in Frankfurt/Xetra. A later prospectus notes that Merck was recorded as a KGaA in July 1995, and another prospectus notes that the shares are admitted to Frankfurt’s regulated market and Prime Standard. In 2007 Merck entered the DAX. The capital-markets story at listing was fairly different from today’s one: investors were buying a historic German science group with family control, not a pure-play biotech-tools compounder or a focused specialty pharmaceutical company. The “conglomerate discount” problem is old, not new.

Merck’s development can be divided into four broad stages. The first was the pre-2000 stage of formal capitalization: the company entered public markets without surrendering family control, which set the permanent governance frame. The second was the portfolio-building stage, when Merck used acquisitions to broaden beyond legacy pharma and chemicals into life-science tools and high-tech materials, creating the three-sector structure investors see today. The third was the pandemic and post-pandemic distortion stage. In 2020-2022 the group benefited from unusually strong demand in life-science workflows and bioprocessing, which pushed sales from €17.5 billion in 2020 to €22.2 billion in 2022 and EBITDA pre from €5.2 billion to €6.8 billion. The fourth is the current digestion-and-reacceleration stage: 2023 was a transition year shaped by destocking and semiconductor cyclicality, 2024 stabilized, and 2025-2026 are forcing the company to prove that Life Science and Electronics can again overcome Healthcare’s drag.

The key recent nodes are clearer than the distant ones because the group now discloses them in detail. In April 2025 Merck signed the SpringWorks acquisition at an equity value of about $3.9 billion and an enterprise value of $3.4 billion, the largest deal it had done in years, to add rare-disease and oncology assets to Healthcare. The transaction closed on July 1, 2025 and was a direct response to looming patent expiries and a weak internally generated pipeline. In October 2025 Merck announced the acquisition of JSR Life Sciences’ chromatography business; it closed on March 31, 2026 and was folded into Process Solutions. A month after the SpringWorks deal was announced, Merck also refreshed management: internal leaders were elevated across key businesses in 2025, and in September 2025 E. Merck KG appointed Kai Beckmann to succeed Belén Garijo as CEO from May 1, 2026. That succession choice was telling. The board chose the executive most associated with the Electronics franchise and the broader technology identity of the group, not a Healthcare outsider brought in to turn pharma around.

Today’s business model is easiest to understand by thinking in cash layers rather than reported segments. Healthcare is the layer that carries patent, clinical and regulatory risk. It contains the highest-value intellectual property, but also the sharpest binary outcomes. Life Science is the layer that monetizes scientific activity with a mix of recurring consumables, process materials, services and equipment. That revenue is less binary, often more repeatable and usually more cash-convertible over time, though the 2023-2024 digestion showed that even “picks and shovels” businesses can suffer from customer destocking. Electronics is the layer that sells enabling materials into semiconductor and display manufacturing. That arm is cyclical, but it can be quietly attractive when device complexity rises and customers need local, validated, low-defect materials rather than generic chemicals.

The 2025 numbers show the shape of that machine. Group sales were €21.1 billion and EBITDA pre was €6.1 billion, nearly flat in reported terms because organic growth of 5.6% was offset by about 5.0% of currency headwind. The annual report shows free cash flow of €2.05 billion and investment payments of €1.96 billion, adjusted to €1.76 billion after excluding irregular collaboration and licensing items. Net financial debt rose to €8.62 billion, largely because of the SpringWorks acquisition, but Q1 2026 already brought that down to €8.32 billion. The balance sheet is therefore more levered than it was before the deal wave, but still consistent with investment-grade ratings of A at S&P and A3 at Moody’s, both with stable outlooks.

Cash conversion is good enough to matter, but not good enough to pretend capex is trivial. Over 2021-2025, operating cash flow summed to about €21.2 billion against roughly €14.6 billion of profit after tax, an operating-cash-flow-to-net-income ratio of about 1.45 times. That is healthy. But 2025 also shows why headline “pre” earnings can flatter the economics of a capital-intensive science group. Free cash flow was €2.05 billion, well below EBITDA pre, because working capital swung negative and capex remained high. Depreciation, amortization and impairments totaled €1.93 billion in 2025, while adjusted investment payments were €1.76 billion. That suggests Merck is not underinvesting, and it also suggests maintenance capex is meaningful. A reasonable research assumption is that roughly €1.1 billion of annual capex is maintenance and the rest is growth. On that basis, owner earnings sit around €2.8 billion, or about €6.5 per theoretical share: higher than IFRS EPS, but materially below EPS pre. The stock therefore looks cheaper on Merck’s preferred earnings metric than on owner earnings.

The moat is strongest in Life Science and narrowest in Healthcare. In Life Science, Merck benefits from deep catalog breadth, validated workflows, process know-how and switching costs in regulated biopharma manufacturing. The announced acquisition of JSR’s chromatography business fits that moat exactly: it was not a leap into an unrelated adjacence, but a deepening of a workflow Merck already serves. In Electronics, the moat is more technical and customer-embedded. Merck’s Q1 2026 report tied semiconductor-material growth directly to demand for advanced nodes and AI chips, while management highlighted that Thin Films had set a record in late 2025. Those are not commodity positions. Healthcare, by contrast, still has valuable franchises such as Mavenclad and Erbitux, but the pipeline has plainly lost some credibility after evobrutinib and xevinapant disappointments, and management itself has discussed the need to rebuild the earlier-stage pipeline.

Governance is the reason Merck should not trade like the cleanest science-platform names. The annual report is unusually explicit: E. Merck KG participates in net profit transfers in line with its 70.274% equity interest, while listed shareholders participate according to the 29.726% subscribed capital share. That is not a regular one-share-one-vote equity story. It is a controlled partnership limited by shares, and the family general partner keeps strategic control with only partial public float. That structure can be beneficial when it protects long-term investment and discourages short-term optimization. It can also entrench strategic ambiguity and limit any real possibility of a breakup, spin-off or activist-driven restructuring even if the market keeps applying a conglomerate discount. Investors need to value the stock with that permanent handicap in mind.

Industry, cycle, and horizontal competition

Merck sits inside three different industry structures, and that is why simple peer work fails. The Life Science sector competes against highly systematized workflow companies. Danaher’s biotechnology arm and Thermo Fisher’s broad serving-science model are the best global reference points, while Sartorius is the most relevant European benchmark for bioprocessing purity. Danaher reported 2025 revenue of roughly $24.4 billion and entered 2026 with bioprocessing demand recovering; Reuters described its 2026 results as benefiting from strong bioprocessing demand. Thermo Fisher reported 2025 revenue of $44.6 billion, with continued strength in pharma demand but weaker academic and government spending. Sartorius reported €3.54 billion of 2025 sales with a 29.7% underlying EBITDA margin and returned to solid constant-currency growth in Q1 2026. Put bluntly, Merck’s Life Science unit is competing in a field where customers buy reliability, validation and global service more than headline instrument features. Merck is not the largest company in that peer set, but it is credible in the part of the market where process integration and consumables matter most.

The comparison reveals what Merck is and is not. Thermo Fisher and Danaher are broader, cleaner and easier for the market to underwrite because almost all of their narrative sits inside “tools and services.” They also still command richer equity valuations: Reuters shows Danaher at about $130 billion of market cap and roughly 35.8 times earnings, and Thermo Fisher at roughly $175.7 billion and about 26.0 times earnings. Merck, by contrast, sits near €58.1 billion and about 15.9 times 2025 EPS pre, partly because the market capitalizes its healthcare risk and governance discount together. The gap is not just sentiment. Danaher and Thermo have less pharma patent-cliff risk embedded in the listed vehicle. Merck’s discount is therefore mostly rational, not merely neglected.

Merck’s Life Science franchise still compares well on business quality. The annual report shows Life Science delivered €3.08 billion of EBITDA pre in 2025, with a margin of 35.8%. Sartorius reported a 29.7% underlying EBITDA margin in 2025, while Entegris reported a 2025 EBITDA margin around 28%. Danaher and Thermo are broader groups, so direct segment-level comparisons are imperfect, but both companies’ recent results confirm the same industry pattern Merck is seeing: consumables and bioprocessing are healthier than headlines around academic budgets suggest. Merck’s problem is not that Life Science is poor. It is that the whole listed vehicle does not let investors own that franchise in isolation.

Electronics is a different market altogether. Here Merck is best thought of as an enabling-materials specialist that sits below the glamour layer of semiconductors but above generic chemicals. Competition comes from Entegris, DuPont’s electronics businesses, Tokyo Ohka, Shin-Etsu and JSR, each with different strengths in filters, specialty materials, photoresists, wafers or process chemicals. SEMI said in late 2025 that foundry and logic wafer-fab-equipment spending was expected to rise 9.8% in 2025 and 5.5% in 2026, driven by advanced nodes and AI accelerators. Merck’s own Q1 2026 reporting ties Semiconductor Solutions growth directly to demand for advanced nodes in AI. Tokyo Ohka’s latest annual results point in the same direction: front-end semiconductor photoresist revenues rose 15% in FY2025. Shin-Etsu has also continued investing in lithography-material capacity, including a new Gunma plant announced in 2024. This is not a one-quarter fad. It is a multi-year capacity-and-complexity buildout, though still a cyclical one.

That said, Merck is not the dominant listed semiconductor-materials franchise. Entegris is the cleaner U.S. advanced-materials peer, with about $19.1 billion of market cap and a much higher earnings multiple, reflecting stronger semiconductor purity and a more focused narrative. Merck’s advantage is breadth across specialty materials and its ability to fund those positions through a larger, more diversified group. Its disadvantage is that Electronics also contains weaker display exposures and, until the 2025 divestment, non-core surface-solutions activities. Merck’s decision to sell Surface Solutions in 2025 was a healthy move toward portfolio clarity, but it also sharpened the remaining truth: this business now wins or loses more directly on semiconductor materials, not on being a catch-all advanced-materials bucket.

Healthcare is where Merck looks worst in horizontal perspective. UCB is not a perfect peer, but it is a useful one because it shows what the market pays for a specialty pharma company with visible new-product momentum. UCB ended 2025 with €7.741 billion of revenue and a market cap around €49.1 billion; corrected adjusted EBITDA margin was about 31.4%, and its 2026 guidance points to high-single-digit to low-double-digit revenue growth. Reuters shows UCB trading at roughly 31 times earnings. Merck’s Healthcare business does not command that type of enthusiasm because its late-stage record has been shakier, its patent cliff is live, and recent M&A has been more defensive than category-defining. On this axis the bears are right: Merck’s pharma business is the least premium-worthy part of the portfolio.

The ecological niche is therefore unusual. Merck is not the cost leader, not the pure innovation premium stock, and not the highest-yielding mature cash cow. It occupies a middle position as a diversified science platform whose real profit pool increasingly comes from industrially embedded science: biologics manufacturing tools, validated production workflows and specialty semiconductor materials. Where does it take profit from? In Life Science it takes share from narrower bioprocessing vendors when customers want workflow depth and global reach. In Electronics it participates in the rising share of semiconductor value captured by process materials as node complexity climbs. Who threatens its profit pool? In Life Science, Danaher, Thermo and Sartorius if they out-innovate or underprice in specific workflows; in Electronics, focused Japanese and U.S. materials specialists; in Healthcare, time itself, via exclusivity loss, and competitors with stronger late-stage pipelines.

Policy and geopolitics matter differently by segment. Healthcare faces ordinary pharma risks: pricing pressure, patent litigation, approvals and reimbursement. Life Science faces funding cycles in biotech, academia and government research; Thermo Fisher’s 2026 commentary on weak U.S. and Chinese academic demand shows that this is not hypothetical. Electronics faces the most explicit geopolitics. Semiconductor supply-chain localization, export controls and industrial policy can help demand while complicating footprints. Merck’s own Q1 2026 guidance also acknowledged geopolitics more directly than usual, including assumptions about the Gulf conflict and the U.S. dollar. This is a company with global demand but also global exposure. Diversification helps, but it does not make the group non-cyclical.

Current fundamentals and market debate

The last four reported quarters tell a story of improving operating quality outside Healthcare. Q2 2025 delivered organic sales growth of 2.0% and organic EBITDA pre growth of 4.6%, with strength in Process Solutions, Mavenclad, Erbitux and Semiconductor Materials. Q3 2025 accelerated to 5.2% organic sales growth and 8.8% organic EBITDA pre growth, with Process Solutions, Rare Diseases and Semiconductor Solutions called out as standouts. Full-year 2025 landed at €21.1 billion of sales and €6.1 billion of EBITDA pre, solid enough on the face of it, but accompanied by a cautious 2026 guide. Then Q1 2026 came in stronger than feared: sales rose organically, EBITDA pre beat expectations, and guidance was raised. This pattern matters because it shows the year did not deteriorate sequentially across the portfolio. Instead, Healthcare weakened while the other two sectors kept firming.

The Q1 2026 sector data are the cleanest current read-through. Electronics reported €817 million of Q1 sales, down 13.9% reported because of foreign exchange and the Surface Solutions divestment, but up 4.2% organically; Semiconductor Solutions grew 7.5% organically, with semiconductor materials in the low teens. At the group level, Merck lifted 2026 guidance to €20.4 billion to €21.4 billion of sales and €5.7 billion to €6.1 billion of EBITDA pre. Life Science is now guided to 4% to 7% organic sales growth; Electronics to 3% to 7%; Healthcare to a 6% to 3% organic decline. The company also disclosed that the guide no longer assumed U.S. Mavenclad sales after May 2026 rather than March, which helped explain some of the upward revision.

The market is trading three things right now. First, whether the Mavenclad cliff is a one-year earnings hole or proof that Merck’s Healthcare business deserves a permanently lower multiple. Second, whether bioprocessing demand has moved from “recovery hope” to “recovery fact.” Reuters’ reporting on Danaher and Thermo Fisher suggests the broader industry is indeed seeing improving pharma and bioprocessing demand, which supports Merck’s Life Science claims. Third, whether AI-driven semiconductor spending can stay strong enough to offset display softness and foreign-exchange pressure inside Electronics. The market is not assigning Merck a single dominant theme; it is weighing offsetting ones.

The bull case rests on evidence, not optimism. Process Solutions growth was not a one-quarter bounce. Merck said in its March 2026 reporting that the business had delivered around 10% organic growth for four consecutive quarters, and the Q1 2026 update then lifted full-year Life Science guidance because demand was still stronger than previously expected. Electronics also has factual support: Merck explicitly tied expected growth to semiconductor materials for advanced-node AI chips, and industry forecasts from SEMI remain supportive of foundry/logic equipment spending. On top of that, the balance sheet, though more levered after SpringWorks, still carries stable investment-grade ratings and saw net debt fall in Q1 2026. The bull thesis is therefore not “sold off equals cheap.” It is “the strongest earnings engines are improving while the biggest headwind is visible and partly annualizing.”

The bear case is also evidence-based. Healthcare’s decline is not just Mavenclad noise. It follows a sequence of pipeline disappointments, including evobrutinib in 2023 and xevinapant in 2024, and management has openly signaled that earlier-stage pipeline depth needs rebuilding. SpringWorks partly addresses that, but it also adds execution burden and more debt while not fully solving the underlying issue of internally generated pharma innovation. The KGaA structure then limits the usual capital-markets remedy: if value would be higher through a spin or a cleaner sector focus, minority holders have little practical way to force it. That is why the market still prices Merck more cheaply than the best pure-play peers even after the May rebound.

My read is that the market is still misjudging one thing, but only one thing. It is somewhat too eager to let the Healthcare narrative dominate the group story. That was understandable at the March guide, when the stock was reacting to a fresh earnings reset. It is less appropriate after Q1 2026, when Life Science and Electronics had once again demonstrated that they are not passenger businesses. But that partial mispricing is not enough, at today’s price, to turn the stock into a clear buy. The market may be slightly too gloomy on the quality of the non-Healthcare businesses, yet it is not obviously underpricing the governance discount or the pharma execution risk.

Valuation, risks, and tracking indicators

Merck’s current valuation sits in a much less exuberant place than the company occupied during the best part of the pandemic-era tools boom, but it is not at a capitulation level either. Using the 2026-06-18 close of €133.05 and the theoretical share count implied by Merck’s own disclosures, equity value is about €58.1 billion. Using year-end 2025 net debt of €8.62 billion gives an enterprise value near €66.7 billion, or about 10.9 times 2025 EBITDA pre. On 2025 EPS pre of €8.34, the stock trades at roughly 15.9 times. On 2025 free cash flow of €2.05 billion, the free-cash-flow yield is only about 3.5%. If one uses owner earnings rather than EPS pre, assuming around €1.1 billion of maintenance capex and the balance of 2025 adjusted capex as growth, the implied owner-earnings yield is closer to 4.8% and the stock trades around 20 times owner earnings. The multiple is therefore not demanding relative to elite science-platform peers, but the cash yield is not a bargain against a 2.9%-ish Bund either.

Peer valuation reinforces the “fair but not cheap” conclusion. Danaher and Thermo Fisher still trade at meaningfully higher earnings multiples, reflecting cleaner business mixes and less listed-vehicle exposure to patent cliffs. Entegris is even richer on earnings because the market pays for semiconductor-materials purity and focus. UCB trades at a much higher earnings multiple because its market story is that of a specialty-pharma growth phase, not an exposed patent-cliff phase. Merck deserves some discount to each of those names, but not the same discount to all of them. Relative to Danaher and Thermo, Merck’s discount is partly deserved because of portfolio complexity. Relative to UCB, it is deserved because of weaker healthcare momentum. Relative to Entegris, it is deserved because Electronics is only part of Merck, not the whole vehicle. The peer set therefore supports a discount, but not a distressed one.

The cleanest way to value Merck is still EV/EBITDA with a cash-discipline check. Merck itself uses EBITDA pre as the core operating metric, and for this company that is defensible so long as capex is brought back in through the owner-earnings discussion. The scenarios below are therefore built on EBITDA pre, net debt around the Q1 2026 level, and a separate judgment on what multiple a controlled, diversified science group deserves.

These scenarios are valuation analysis inside a research framework, not investment advice. They imply that Merck’s fair value is wide because three businesses are being valued together, and because the governance discount is architectural rather than cyclical.

Expectation-gap analysis points to three variables the market is likely to watch hardest over the next year. The first is Process Solutions organic growth. If that slips back toward low single digits, the market will stop granting Merck much credit for a Life Science-led recovery. The second is the realized slope of Mavenclad erosion. The market can handle a known cliff better than a cliff that keeps moving. The third is evidence that SpringWorks and the broader Healthcare pipeline are doing more than plugging a near-term hole. If Healthcare remains a shrinking cash generator rather than a future growth driver, the group’s rerating ceiling stays low.

Margin of safety is the discipline check. At €133.05, the share price is above the value implied by the conservative scenario and below the optimistic scenario. That means the margin of safety is not zero, but it is also not comfortable. The most fragile assumption in the base case is not semiconductor demand. It is the idea that Life Science can keep outrunning Healthcare while Healthcare at least avoids another credibility event. Cut that assumption to 70%, and the base valuation quickly drifts back toward the low €120s. If earnings were flat for the next three years and the dividend stayed at €2.20, the total annualized return from here would be only modestly above the current Bund yield. This is therefore a classic “good company, middling price” setup. The margin-of-safety sufficiency verdict is: not obvious.

The risks that matter are specific. The biggest business risk is that Healthcare’s patent and pipeline problems prove cumulative rather than isolated. Probability medium; impact high. The observable indicators are new trial failures, lower healthcare guidance, or failure of SpringWorks assets to scale. The transmission path is lower Healthcare EBITDA, lower group confidence, and a more persistent conglomerate discount. The second risk is that Life Science’s recovery is more cyclical than structural. Probability medium; impact medium to high. Watch Process Solutions growth, peer commentary from Danaher and Thermo, and customer funding signals. The third is Electronics mix risk. Probability medium; impact medium. Semiconductor materials are strong, but display-related demand and FX can still drag the segment. The fourth is governance risk. Probability always-on; impact medium. It does not create a one-day collapse, but it permanently narrows the possible rerating range. The fifth is balance-sheet and capital-allocation risk if Merck keeps using M&A to patch Healthcare. Probability medium; impact medium. Stable ratings help, but more defensive acquisitions would consume the valuation discount rather than cure it.

A compact tracking dashboard is more useful than ten pages of forecasting.

Merck itself is the best primary source for the first six indicators. Peers and Reuters are useful for the last two. What matters is not a single print, but whether all three engines are moving together or offsetting each other. That offsetting pattern is the whole investment case.

Cross-synthesis summary

Merck’s long history proves one real capability above all others: it can reinvent its portfolio without losing scientific seriousness or its balance-sheet discipline. That is not trivial. Many old industrial or pharmaceutical houses become museums of prior success; Merck turned itself into a science platform with credible positions in biologics manufacturing and semiconductor materials while keeping an investment-grade balance sheet and a stable dividend. The group’s 2020-2025 numbers still show this endurance. Sales are up about 20% versus 2020, EBITDA pre is up about 17%, and operating cash flow over five years remained robust despite a transition year in 2023 and acquisition-related pressure in 2025. That is the vertical lesson. Merck knows how to migrate its economic center of gravity over time.

The problem is that the current migration is incomplete. In a cleaner portfolio, Life Science would likely be the market’s dominant lens. It has the best moat, the cleanest recurring revenue, the strongest customer stickiness and the clearest peer precedents for premium multiples. Electronics would then be a good cyclical sidecar, particularly at this point in the semiconductor materials cycle. Healthcare would be either a valuable optionality sleeve or a stand-alone specialty-pharma vehicle with a lower multiple. Merck instead asks investors to own all three inside one controlled entity. Sometimes that diversification is valuable. In 2026 it is also the source of the discount. The market cannot decide whether to treat Merck as a compounder, a cyclical recovery or a healthcare repair story because it is all three.

That is why past success should be partitioned carefully. Merck’s recent success did not come from one magical corporate trait. It came from different strengths at different times. The 2020-2022 surge relied heavily on extraordinary Life Science demand and strong execution. The current Electronics recovery relies on semiconductor complexity and AI-led capex. The company’s historical stability owes something to prudent capital structure and family control as well. What does not deserve too much credit is Healthcare innovation over the last few years. There the record is weaker. The sequence of evobrutinib, xevinapant and now the Mavenclad cliff means the market is right to be skeptical until Merck proves otherwise.

Horizontally, Merck’s real advantage versus competitors is that it sits where scientific complexity becomes operational dependence. Customers do not choose Merck because it is the cheapest across the board. They choose it when switching costs are painful, validation matters, defect tolerance is low and workflow depth saves time or risk. That is why Life Science and semiconductor materials are the right centers of gravity for the group. The weakness, however, is also structural. Merck lacks the clean storytelling of Danaher or Thermo Fisher, the focused semiconductor purity of Entegris and the specialty-pharma growth credibility of UCB. Some of that weakness is temporary, especially in Healthcare, if the pipeline rebuild works. Some is structural, because the KGaA form all but guarantees a governance discount.

What is the market most likely misjudging right now? It is probably underestimating how durable the better parts of the portfolio are, but it is probably not underestimating the governance problem. Investors often react to diversified structures by letting the weakest division dominate the narrative. That is happening here. The market talks too much about Mavenclad and too little about the quality of Process Solutions and the rising relevance of semiconductor materials. Yet it is also true that if Merck were an ordinary corporation, some kind of portfolio simplification could eventually force a rerating. In a KGaA under family control, that optionality is much weaker. The stock therefore earns only partial credit for its best assets. That is frustrating, but it is not irrational.

Over the next year, the key variable is whether 2026 guidance gets delivered with Life Science and Electronics doing the heavy lifting while Healthcare declines in an orderly way. Over the next three years, the key variable is whether Healthcare can become more than a profit-defense exercise through SpringWorks, rare disease launches and a rebuilt earlier-stage pipeline. Over five years, the key issue is whether Merck remains a conglomerate that never quite gets its due, or whether management progressively shifts the mix enough that the market starts valuing it more like a science platform and less like a pharma-with-baggage structure. That is where today’s price sits: not on the edge of disaster, not at the start of a clean rerating, but in the middle of a proof phase.

Bull and bear reasons

The bull case has four core reasons. Merck’s best business, Life Science, is already showing recovery that peers broadly corroborate, and it remains the most defensible moat in the portfolio. Electronics has credible AI and advanced-node exposure through materials rather than hype-layer software. The Mavenclad drag is now a known event rather than a hidden risk, and after Q1 2026 even management’s guidance is less severe than the March market feared. Finally, the balance sheet is still investment grade and net debt fell in Q1 2026 despite the acquisition wave.

The bear case also has four core reasons. Healthcare is still the weakest strategic leg and has not repaired investor trust after repeated setbacks. The KGaA and family-control structure justify a persistent discount and sharply reduce the chance of an externally forced breakup or spin. Free cash flow is respectable but not high enough to make the stock an obvious bargain at today’s price. And Merck’s valuation is no longer washed out after the May rebound, so there is limited protection if either Life Science’s recovery cools or Electronics stumbles.

Pre-mortem

Suppose the stock is down 50% by 2029. The most likely script is not a single disaster, but a failed offset. Mavenclad erodes faster than even the current model implies, SpringWorks contributes less than hoped, and no internally developed Healthcare asset reaches clear commercial relevance. At the same time, Process Solutions cools to low single-digit growth after the current rebound and semiconductor materials lose pricing momentum as AI capex normalizes. Group EBITDA pre falls back toward the low €5 billions, the market stops treating Merck as a recovery story, and the EV/EBITDA multiple compresses toward 8x. Under that script the equity could plausibly trade into the €75–90 zone.

A second, softer but still damaging script is governance-led dead money. Life Science and Electronics perform decently, but Healthcare remains mediocre and management responds with more M&A rather than sharper portfolio action. Earnings move sideways to modestly up, but the market keeps applying a permanent holding-company and KGaA discount because there is no realistic catalyst for structural simplification. In that case the stock may not halve quickly, but it can still produce years of poor real returns while peers with cleaner narratives rerate.

Final research conclusion

Merck KGaA is worth owning only if one is comfortable owning three businesses with three different clocks. The best part of the company is the part the market cannot own separately: Life Science, with its process depth, recurring consumables and customer stickiness. Electronics adds a valuable, technically grounded semiconductor-materials growth vector. Healthcare is the drag, not because it lacks revenue, but because it lacks enough credibility to carry a premium multiple right now. The family-controlled KGaA structure then caps how much of the upside from the stronger assets is ever likely to be fully recognized in the stock.

At today’s price, that mix does not amount to a classic buy. The stock is no longer being priced for a March-style earnings shock, but it is also not being valued like a clean science-platform compounder. I think current pricing is broadly fair. The mistake would be to read that as a verdict on business quality. Merck still has quality assets and genuine technical strengths. The issue is that quality and attractiveness are not the same thing when governance is restrictive, pharma execution is uneven and free-cash-flow yield is only moderate. What would change my mind? Either a materially lower entry price, or harder proof that Healthcare can be rebuilt without repeated expensive patching.

【Company-profile scores】

• Fundamental quality: medium
• Growth: medium
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: Strong Life Science and semiconductor materials offset a known Healthcare cliff, but governance discount and only fair valuation keep upside limited.

【Ideal Buy Price】90–95 EUR Basis: at least a 20% discount to the conservative fair-value range of about €112–118 per share.

• Acceptable hold price: 119–161 EUR
• Clearly overvalued price: 180 EUR and above
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. For new money, a buy becomes attractive below about €95 if Life Science still grows above 4% organically and Healthcare deterioration remains bounded. The opportunity cost of waiting is forgoing a plausible mid-single-digit total return, not missing an obvious compounding machine.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative about -3% to 0%; base about 3% to 5%; optimistic about 9% to 11%
• Max-loss risk: roughly 35% to 45% from current levels if Healthcare disappoints again while Life Science and Electronics also soften, pushing the multiple toward 8x EV/EBITDA
• Reassessment-trigger signals: Process Solutions organic growth below 3% for two consecutive quarters; Healthcare organic decline worse than -8%; net debt / EBITDA pre above 1.8x without a clear strategic payoff; any major late-stage Healthcare failure that further harms pipeline credibility; Electronics semiconductor-materials growth turning negative for two consecutive quarters

【Valuation Range】

• current: 133.05 (close as of 2026-06-18)
• bear (conservative · ideal buy zone): [90, 95]
• base (fair · acceptable hold zone): [119, 161]
• bull (optimistic · above the clearly-overvalued line): [180, 195]

Research uncertainties

The main blind spot is healthcare valuation inside the group. Merck’s external reporting is good on current performance, but any sum-of-parts view still requires judgment about how much value the market should assign to SpringWorks and to a pipeline that management itself says needs rebuilding.

The second uncertainty is maintenance versus growth capex. Merck’s disclosures clearly show total and adjusted investment payments, but not a formal split between sustaining and growth capital. The owner-earnings estimates above therefore rely on research judgment, not company guidance.

The third is the persistence of the semiconductor upcycle. Industry and company data support AI-driven strength today, but material suppliers still live inside a cyclical chain, and a cleaner read will require several more quarters.

The fourth is governance optionality. The discount for the KGaA structure is real, but its exact size cannot be observed directly because no clean counterfactual exists in which Merck’s portfolio is controlled through a standard equity structure.

Sources

Primary sources used in this report were Merck KGaA’s FY2025 annual report, Q1 2026 report and press release, investor share-data pages, creditor-relations materials, governance and executive-transition disclosures, AGM materials, and transaction releases for SpringWorks and JSR.

Sector and peer context came mainly from Danaher, Thermo Fisher, Sartorius, UCB, Entegris, Tokyo Ohka and Shin-Etsu disclosures, supplemented by Reuters reporting and SEMI data on equipment spending and market conditions.

Market and macro context for current pricing, selloffs, rebounds, bond yields and FX conversions came from Reuters, the ECB and exchange/quote pages. ECB reference rates on 2026-06-18 were €1 = $1.1461 and €1 = CNY 7.7609.

Other tickers mentioned

• DHR.US: global life-science and bioprocessing benchmark for Merck’s Life Science business
• TMO.US: broad serving-science peer used to frame Merck’s tools and workflow quality
• SRT3.XETRA: European bioprocessing and lab-tools peer relevant to Merck’s Life Science moat
• ENTG.US: focused semiconductor-materials peer for Merck’s Electronics segment
• UCB.BR: specialty-pharma comparison point for Merck’s Healthcare valuation discount
• DD.US: electronics-materials reference point in semiconductor and industrial specialty materials
• 4186.TSE: Tokyo Ohka, a direct semiconductor photoresist competitor in electronics materials
• 4063.TSE: Shin-Etsu Chemical, a major semiconductor-materials competitor and capacity investor
• 4185.TSE: JSR, mentioned because Merck acquired JSR Life Sciences’ chromatography business
• SWTX.US: SpringWorks Therapeutics, acquired by Merck to reinforce Healthcare

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.